TrialBritish journal of cancer2022

A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA).

Grant D Stewart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.